US biotech NewLimit has raised $435 million in a series C round as it prepares to take its first age-reprogramming medicine ...
Notably, the clinical trials MAGMA and JCOG1703 further demonstrated that some treatment regimens for newly diagnosed GBMs ...
A new study developed a mineralized DNA hydrogel that combines immune regulation with sustained bone regeneration. Using ...
Despite the technological marvels, 2026 has seen a powerful return to ancestral wisdom. The Bio-Hacking movement has evolved ...
NewLimit, which plans to take its young-again cell reprogramming therapy into the clinic next year, raised a $435 million ...
Plus: Hackers use Meta’s AI bots to hack Instagram accounts, Anthropic helps NSA hackers, a decades-long GPS satellite ...
Knowable Magazine reports on a revolutionary CAR T-cell therapy, originally for cancer, now showing promise for autoimmune ...
Longevity start-up NewLimit has raised an eye-watering $435 million to take its lead age reprogramming candidate into human ...
Ractigen Therapeutics has presented late-breaking preclinical data at ADA 2026 showing its LiCO-saUcp1 saRNA therapy converts ...
A new study in Nature Cancer found that montelukast, a common asthma drug, blocks a molecule called CysLTR1 that tumours use ...
The Xteink X4 is easy to pass on, easier to become a part of your every day carry, and an irresistibly charming device that just might win over the bibliophile inside you without hurting your wallet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results